NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Caplight Logo









ConcertAI

ConcertAI

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.concertai.com

Last Round

Series C

Mar 29, 2022

Est. Valuation

$1.9B

Total Funding Raised

$300M

Company Overview

ConcertAI is a leader in providing Real-World Data (RWD) and enterprise AI solutions tailored for the life sciences and healthcare sectors. The company's mission is to accelerate medical insights and improve patient outcomes by leveraging its AI-powered SaaS platform. This platform supports the entire lifecycle of therapeutics, from enhancing clinical trial design and execution to providing clinical decision support. ConcertAI partners with biopharmaceutical companies, healthcare providers, medical societies, and regulatory bodies to advance precision medicine. The company has raised $300 million in funding, achieving a valuation of $1.9 billion in its March 2022 Series C round.

Sector

Healthcare & Life Sciences

Verticals

Medical AI, Clinical Trials, Precision Medicine, Healthcare Analytics, Medical Imaging

Business Model

B2B

Customer Profile

Subscription SaaS, Data as a Service, Services & Consulting, Government Contracts

AI Layer

Application

Keywords

real-world dataRWDreal-world evidenceRWEclinical trial optimizationAI for clinical trialsoncology dataagentic AIaccelerated clinical trialsgenerative AIoncology AImedical imaging AImulti-modal dataclinical AI platformregulatory-grade evidenceData as a ServiceDaaSHEOR

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ConcertAI Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

ConcertAI Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series CMar 29, 2022
Series BJan 13, 2020

Key People

Founding team and executive leadership

Jeff Elton

Vice Chairman Former Founding CEO

Founding Team

Michael Myshrall

Chief Financial Officer (CFO) Life Sciences Generative Agentic Artificial Intelligence AI

Executive Team

ConcertAI Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 10, 2026

    CancerLinQ is now part of ConcertAI.

  • Mar 1, 2026

    Launched Precision Trials, a SaaS platform for clinical trial execution.

ConcertAI Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ConcertAI Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ConcertAI's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range835
Year Founded2017
Last FundingMar 29, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.